PMID

Data

Article Title

Organization

Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity.

H. Lee Moffitt Cancer Center and Research Institute

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

H. Lee Moffitt Cancer Center and Research Institute

Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

H. Lee Moffitt Cancer Center and Research Institute

Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.

H. Lee Moffitt Cancer Center and Research Institute

Synthesis of GSK3ß mimetic inhibitors of Akt featuring a novel extended dipeptide surrogate.

H. Lee Moffitt Cancer Center and Research Institute

Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.

H. Lee Moffitt Cancer Center and Research Institute

Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.

H. Lee Moffitt Cancer Center and Research Institute

New ZW4864 Derivatives as Small-Molecule Inhibitors for the β-Catenin/BCL9 Protein-Protein Interaction.

H. Lee Moffitt Cancer Center and Research Institute

Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain.

H. Lee Moffitt Cancer Center and Research Institute

Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.

H. Lee Moffitt Cancer Center and Research Institute

Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.

H. Lee Moffitt Cancer Center and Research Institute

Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.

H. Lee Moffitt Cancer Center and Research Institute

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

H. Lee Moffitt Cancer Center and Research Institute

A Versatile Method to Determine the Cellular Bioavailability of Small-Molecule Inhibitors.

H. Lee Moffitt Cancer Center and Research Institute

NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF

Xizang Haisco Pharmaceutical Co.

PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS

Hoffmann-La Roche

NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS

Ogeda

SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN

St. Jude Children'S Research Hospital

COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY

Case Western Reserve University

COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT

University of Queensland

Opioid receptor modulators

Epiodyne

Benzimidazol-2-amines as mIDH1 inhibitors

Bayer Pharma Aktiengesellschaft

PDE9 inhibitors with imidazo triazinone backbone

TBA

Structure-activity relationships of bergenin derivatives effect on a-glucosidase inhibition.

Kinki University

Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.

University of Karachi

Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof

Ambit Biosciences

Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition.

Genentech

Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay.

Pharmaleads